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A common diagnostic problem remains in differentiating
by routine histology primary pulmonary adenocarcinoma
from adenocarcinoma metastatic to the lung (eg, originating
from breast, gastric, colon, thyroid, pancreas or renal cancers)
[1,2]. Pathologists are often asked to identify the primary
site. It has been reported that immunohistochemistry is a
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Thyroid transcription factor-1 (TTF-1), and cytokeratin 7 (CK7) and cytokeratin 20 (CK20) have recently been
reported to be useful to distinguish between primary and metastatic lung adenocarcinoma. The aim of this
study was to determine the usefulness of the staining patterns of pulmonary adenocarcinoma with
antibodies to TTF-1, CK7, and CK20 in differentiating primary from metastatic pulmonary adenocarcinoma.
Of the 66 lung adenocarcinoma specimens that were enrolled in our study, there were 40 primary lung
adenocarcinomas, 12 metastatic adenocarcinomas from breast, 13 metastatic adenocarcinomas from colon,
and 1 metastatic adenocarcinoma from stomach. The expression of TTF-1, CK7, and CK20
was assessed by immunohistochemistry. We found that 73% of primary lung adenocarcinomas expressed
TTF-1, whereas all nonpulmonary adenocarcinomas lacked TTF-1 staining. CK7 expression was significantly
more frequent in adenocarcinomas of pulmonary and breast origin than gastrointestinal (GI) origin
(p < 0.001). In contrast, CK20 expression was significantly more prevalent in adenocarcinoma that originated
in the GI tract than that of pulmonary or breast origin (p < 0.001). A combination of TTF-1+CK7+CK20– was
highly significantly associated with primary adenocarcinoma of lung (vs GI tract, p < 0.001; vs breast,
p < 0.001). A combination of TTF-1–CKCK20+ was highly significantly associated with adenocarcinoma of
GI origin (vs lung, p < 0.001; vs breast, p < 0.001). Our study has confirmed that expression of CK7, CK20,
and TTF-1 is a useful immunohistochemical marker for diagnosis of lung tumors and for differential
diagnosis of primary pulmonary adenocarcinomas from extrapulmonary adenocarcinomas metastatic to
the lung. Application of this panel of antibodies might be expected to increase the accuracy of diagnosis.
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useful method for ascertaining the site of origin in
such cases. A review of recent studies reveals that the
immunohistochemical markers surfactant protein-B, PE-10,
thyroid transcription factor-1 (TTF-1), cytokeratin 20 (CK20),
and cytokeratin 7 (CK7) have efficacy for discriminating
between primary and metastatic pulmonary adenocarcinoma
[1–5]. In clinical situations, because the most prevalent sites
of adenocarcinoma are in the lungs, colon, and breast, a
combined analysis of TTF-1, CK7, and CK20 expression
may have high sensitivity and specificity for the separation
of primary lung adenocarcinomas from metastatic
adenocarcinomas of colonic or breast origin [1–4].
© 2006 Elsevier. All rights reserved.
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TTF-1 is a member of the NKX2 family of homeodomain
transcription factors [6]. It is a 38-kDa protein, located
primarily in the nuclei of type II pneumocytes and Clara’s
cells in the lung, thyroid tissues, and the diencephalons of
the brain [7,8]. In the lung, it binds to and helps regulate
Clara’s cell secretory and surfactant A, B, and C protein
gene expression [9–11]. In addition, it has also been observed
in 75–80% of pulmonary adenocarcinomas [1].
Although both CK7 and CK20 are intermediate filaments,
they are located in different epithelial cells. CK7, a 54-kDa
basic protein, is typically located in epithelia from lung and
breast; CK20, a 46-kDa acidic cytokeratin protein, is common
in epithelia from the intestinal tract [2].
Thus, in this present study, we studied the staining
patterns of pulmonary adenocarcinoma with antibodies to
TTF-1, CK7, and CK20, so as to confirm the usefulness of
this panel in differentiating primary from metastatic
pulmonary adenocarcinoma.
MATERIALS AND METHODS
Tissue specimens were obtained from 66 cases of lung
adenocarcinoma diagnosed at the Department of Pathology,
Kaohsiung Medical University Chung-Ho Memorial
Hospital, between 1998 and 2004. All tumors were surgical
resection specimens. There were 40 primary pulmonary
adenocarcinomas, 12 metastatic adenocarcinomas from
breast, 13 metastatic adenocarcinomas from colon, and 1
metastatic adenocarcinoma from stomach.
Formalin-fixed, paraffin-embedded tissue specimens
were investigated. For immunostaining, deparaffinized
and rehydrated sections were heated in an oven at 121°C for
30 minutes in citrate buffer to retrieve antigenic activity and
then cooled at room temperature. Endogenous peroxidase
activity was inhibited by incubation with 0.3% hydrogen
peroxide in methanol for 20 minutes. After nonspecific
reactions had been blocked with 10% normal bovine serum,
the sections were incubated with monoclonal antibodies
specific to TTF-1 (1:50; M3575; DAKO), to CK7 (1:50; M7018;
DAKO), and to CK20 (1:50; M7019; DAKO) for 40 minutes.
The sections were then incubated with biotinylated goat
anti-mouse immunoglobulin (Ig) for 20 minutes and then
with streptavidin–peroxidase complex for 20 minutes.
Careful rinses were performed with several changes of
phosphate-buffered saline between each stage of the
procedure. Finally, the color was developed with
diaminobenzidine followed by hematoxylin counterstaining
and mounting. Negative controls were performed by
replacing the primary antibody with nonimmune mouse
IgG.
The immunostained specimens were evaluated by two
observers (C-Y.C. and Y-C.S.) without previous knowledge
of their clinicopathologic features. Tumors were considered
negative if staining was found in fewer than 10% of neoplastic
cells and positive if present in more than 10%. The results of
immunostaining with CK7 and CK20 were based on
cytoplasmic staining of neoplastic cells, whereas nuclear
staining was used for TTF-1 (Figure 1A–D).
The r2 test or the Fisher exact test was used to analyze
each two-dimensional table of discrete data. A p value of
less than 0.05 was considered statistically significant.
RESULTS
The patients ranged in age from 22 to 82 years; 26 were men
and 40 were women. TTF-1, CK7, and CK20 positivity was
shown in 73% (29/40), 75% (30/40), and 0% (0/40) of
primary pulmonary adenocarcinomas, respectively. TTF-1,
CK7, and CK20 positivity was shown in 0% (0/12), 50% (6/
12), and 0% (0/12) of secondary adenocarcinomas that
originated in the breast, respectively. TTF-1, CK7, and
CK20 positivity was shown in 0% (0/12), 7% (1/14), and
86% (12/14) of secondary adenocarcinomas that originated
in the colon, respectively. All nonpulmonary adenocarcinomas
lacked TTF-1 staining. CK7 expression was significantly
more frequent in adenocarcinoma of pulmonary and breast
origin than that of GI tract origin (p < 0.001, Table 1). In
contrast, CK20 expression was significantly more prevalent
in adenocarcinoma of GI tract origin than that of pulmonary
and breast origin (p < 0.001, Table 1).
Tumors from the lung, breast, and GI tract were also
compared by evaluating a combination panel of all three
immunostains (TTF-1, CK7, CK20, Table 2). A combination
of TTF-1 positivity, CK7 positivity, and CK20 negativity
was highly significantly associated with primary pulmonary
adenocarcinoma compared with any of the other tumor
types (p < 0.001). The sensitivity and specificity of this
combination of immunomarkers for a primary lung
adenocarcinoma were 60% and 100%, respectively. A
combination of TTF-1 negativity, CK7 negativity, and CK20
positivity was highly significantly associated with
adenocarcinoma of GI origin compared with either of the
other tumor types (vs lung, p < 0.001; vs breast, p < 0.001).
The sensitivity and specificity of this combination of
immunomarkers for a secondary adenocarcinoma from the
GI tract were 79% and 100%, respectively.
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Table 1. Summary of TTF-1, CK7, and CK20 expression in primary and secondary adenocarcinoma of lung
Immunomarker Lung origin Breast origin GI tract origin
(n = 40) (n = 12) (n = 14)
TTF-1
Positive 29 (73%)* 0 (0%) 0 (0%)
Negative 11 (27%) 12 (100%) 14 (100%)
CK7
Positive 30 (75%)† 6 (50%)‡ 1 (7%)
Negative 10 (25%) 6 (50%) 13 (93%)
 CK20
Positive 0 (0%) 0 (0%) 12 (86%)§
Negative 40 (100%) 12 (100%) 2 (14%)
TTF-1 = thyroid transcription factor-1; CK7 = cytokeratin 7; CK20 = cytokeratin 20.
*Lung (73%) vs breast (0%) or lung (73%) vs GI tract (0%), p < 0.001.
†Lung (75%) vs GI tract (7%), p < 0.001.
‡Breast (50%) vs GI tract (7%), p < 0.001.
§GI tract (86%) vs breast (0%) or GI tract (86%) vs lung (0%), p < 0.001.
Figure 1. (A) Negative control. (B) Primary lung adenocarcinoma showing strong staining for TTF-1. (C) Breast origin lung adenocarcinoma
showing strong staining for CK7. (D) Colon origin lung adenocarcinoma showing strong staining for CK20. (A–D, original magnification × 200).
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DISCUSSION
It is important to distinguish between primary pulmonary
a d e n o c a r c i n o m a  a n d  m e t a s t a t i c  p u l m o n a r y
adenocarcinoma, because the treatment and prognosis differ
considerably for patients with these malignancies. In the
study presented here, we compared three antibodies—TTF-1,
CK7, and CK20—as markers of primary and metastatic
lung adenocarcinoma. Our results determined the sensitivity
and specificity of the antibodies as markers of primary and
metastatic epithelial lung tumors. In addition, the use of a
combination panel of these three immunostains provides
valuable information for the differential diagnosis of lung
adenocarcinoma.
According to many previous studies, TTF-1 is a tissue-
specific gene expression marker that has been reported to
play a crucial role in the molecular pathogenesis of primary
adenocarcinoma of the lungs [12]. In addition, some studies
found that the extent of differentiation and histologic
features correlated with the intensity of TTF-1 staining; for
example, poorly differentiated and solid tumors producing
mucin were less likely to stain [12–14]. Recently, those cases
with positive TTF-1 expression have also been found to be
associated with better patient survival than those with
negative TTF-1 expression [15]. Our study found that TTF-
1 has not only high sensitivity but also high specificity for
primary adenocarcinoma of the lungs. Thus, for clinical
practice, TTF-1 could serve as a reliable marker for diagnosis
of primary adenocarcinoma of the lungs.
CK20 has demonstrated activity specific for the normal
intestinal epithelium, the gastric foveolar epithelium, the
umbrella cells of the urothelium, and epidermal Merkel
cells [16]. Thus the antibody labels the majority of
adenocarcinomas of the colon, mucinous ovarian tumors,
and transitional and Merkel cell carcinomas, and it is often
positive in adenocarcinoma of the stomach, bile duct,
gallbladder, and pancreas [17]. Adenocarcinomas of the
breast, lung, and ovary are essentially negative [17]. The
most frequent CK20+ carcinoma type is adenocarcinoma of
the colon and rectum; however, as the current study shows,
a considerable proportion of colorectal carcinomas do not
react with CK20. Although CK20 positivity (particularly
when it is coupled with CK7 negativity) strongly indicates
a colorectal origin, CK20 negativity (with or without CK7
negativity) does not necessarily rule out this possibility
[18–20].
CK7 is known to label several types of normal and
neoplastic glandular epithelia; carcinomas from the GI tract
and prostate generally are negative, whereas breast, lung,
and subtypes of adenocarcinomas of the ovary generally
are positive [21]. In this study, we found that CK7 staining
was equivocal for adenocarcinoma of breast origin, and it
also could be rarely expressed by secondary adenocarcinoma
of the GI tract (7%).
Since the early 1990s, the clinical utility of monoclonal
antibodies directed against CK20 paired with anti-CK7
antibodies in the differential diagnosis of primary lung
cancers and secondary lung cancers has been reported [22].
Table 2. Summary of TTF-1/CK7/CK20 immunomarker panels in primary and secondary adenocarcinoma of lung
Panel of immunomarker Lung origin* Breast origin GI tract origin
(n = 40) (n = 12) (n = 14)
1. TTF-1+CK7+CK20+ 0 0 0
2. TTF-1+CK7+CK20– 24 (60%)† 0 0
3. TTF-1+CK7–CK20+ 0 0 0
4. TTF-1+CK7–CK20– 5 (13%) 0 0
5. TTF-1–CK7+CK20+ 0 0 1 (7%)
6. TTF-1–CK7+CK20– 6 (15%) 6 (50%) 0
7. TTF-1–CK7–CK20+ 0‡ 0§ 11 (79%)
8. TTF-1–/CK7–/CK20– 5 (13%) 6 (50%) 2 (14%)
TTF-1 = thyroid transcription factor-1; CK7 = cytokeratin 7; CK20 = cytokeratin 20.
*Sensitivity/specificity for lung origin adenocarcinomas panels: 1, 0%/100%; 2, 60%/100%; 3, 0%/100%; 4, 5%/100%; 5, 0%/96%; 6, 15%/77%;
7, 0%/58%; 8, 3%/69%.
†Lung vs breast or GI tract, p < 0.001; sensitivity 50%, specificity 100%.
‡GI tract vs lung, p < 0.001.
§GI tract vs breast, p < 0.001.
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Adenocarcinoma from the colon is usually CK20+ and CK7–,
whereas adenocarcinoma from the lung is usually CK20–
and CK7+ [3].
There seems to be a strong indication in the literature
that the use of an antibody panel combining CK7, CK20,
and TTF-1 in differentiating between primary and
metastatic adenocarcinomas of the lung is reliable [2].
In our study, we noted that, when TTF-1 was used in
conjunction with CK7 and CK20, it was useful in
discriminating between primary and metastatic
adenocarcinomas of the lung. The combination of the
CK7+CK20– immunophenotype, along with TTF-1
immunoreactivity, was highly specific for primary
pulmonary adenocarcinoma (specificity 100%).
CONCLUSIONS
Our study has confirmed that CK7, CK20, and TTF-1
expression are useful as immunohistochemical markers for
the diagnosis of lung tumors and for the differential
diagnosis of primary pulmonary adenocarcinomas from
extrapulmonary adenocarcinomas metastatic to the lung.
Application of this panel of antibodies might be expected to
increase the accuracy of diagnosis.
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